Daewoong Pharmaceutical
Jeesun Lee has a diverse work experience in the medical and pharmaceutical field. Jeesun recently joined Daewoong Pharmaceuticals as the Head of Clinical Development Center in 2022. Prior to this, they worked at Shaperon as a Clinical Development Director from 2021 to 2022, where they played a key role in the Covid 19 pneumonia Phase 2b/3 clinical trial and provided medical insight for drug development plans. Before that, they worked at Pfizer from 2014 to 2021, holding various roles such as Korea Oncology BU Medical Lead and Global Established Pharmaceutical, Medical Manager. Jeesun started their career as a Resident Physician at Seoul National University Hospital and interned at a medical institution in 2009.
Jeesun Lee has a Ph.D in Clinical Epidemiology from Sungkyunkwan University. Additionally, they hold a Master of Public Health (MPH) degree from Seoul National University. Jeesun also studied Medicine at Korea University.
This person is not in any teams
Daewoong Pharmaceutical
Establish in 1945, Daewoong Pharmaceuticals Co., Ltd. is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both domestic and international markets. Through our strong M&S divisions, Daewoong has the largest prescription drug sales in the South Korean market. Presently, we commercialize 10 blockbuster products. In addition, we have built a strong internal core competency for new drug development and have expanded regional and global collaborations with international partners. To reach our goal to become a global health care company, Daewoong has expanded international operations establishing branches offices throughout Asia and research centers in the US, China, and India. Currently, Daewoong is constructing a new manufacturing facility under cGMP guidelines to meet the needs of our global partners.